Genzyme To Sanofi: How About $89-Per-Share? Answer: "Very Unrealistic"
Genzyme is out to convince investors that Sanofi's hostile bid significantly undervalues the biotech, laying out the reasons why at a meeting in New York Oct. 23.
Genzyme is out to convince investors that Sanofi's hostile bid significantly undervalues the biotech, laying out the reasons why at a meeting in New York Oct. 23.